跳至主要内容
临床试验/NCT01736969
NCT01736969Unknown不适用

Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote® Scar Gel for the Management of Hypertrophic or Keloid Scars

Oculus Innovative Sciences, Inc.2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2012年8月最近更新:
适应症

试验速览

阶段
不适用
入组人数
40
试验地点
2
主要终点
Comparison between groups in Vancouver Scar Scale total score from Baseline to Day 112 (or early termination)

研究概览

简要总结

The purpose of this study is to determine whether a developmental formulation is substantially equivalent to the predicate device in the treatment of hypertrophic and keloid scars.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to provide informed consent and release health information
  • Ability to follow study instructions and study requirements
  • Have a hypertrophic or keloid scar accessible for treatment and evaluation
  • Negative pregnancy test for women of childbearing potential
  • Agreement to use effective birth control method for study duration

排除标准

  • History of allergy or sensitivity to components
  • History of diabetes
  • History of collagen vascular disorders
  • Anticipated need for surgery or hospitalization during the study
  • Pregnant, nursing, or planning a pregnancy during the study
  • Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to Baseline (Day 0)

结局指标

主要结局

Comparison between groups in Vancouver Scar Scale total score from Baseline to Day 112 (or early termination)

时间窗: 4 weeks, 8 weeks, 12 weeks

Vascularity, height/thickness, pliability, and pigmentation. Scoring from zero to thirteen.

次要结局

  • Pain and itch(4 weeks, 8 weeks, 12 weeks)
  • Adverse Events(Baseline, Weeks: 2, 4, 8, 12 and early termination)
  • Treatment satisfaction(8 weeks, 12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验